Overview

Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer
Phase:
N/A
Details
Lead Sponsor:
Wirral University Teaching Hospital NHS Trust
Collaborator:
AstraZeneca
Treatments:
Bicalutamide